% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Scuteri:165134,
      author       = {Scuteri, Damiana and Tonin, Paolo and Nicotera, Pierluigi
                      and Vulnera, Marilù and Altieri, Giuseppina Cristina and
                      Tarsitano, Assunta and Bagetta, Giacinto and Corasaniti,
                      Maria Tiziana},
      title        = {{P}ooled {A}nalysis of {R}eal-{W}orld {E}vidence {S}upports
                      {A}nti-{CGRP} m{A}bs and {O}nabotulinumtoxin{A} {C}ombined
                      {T}rial in {C}hronic {M}igraine.},
      journal      = {Toxins},
      volume       = {14},
      number       = {8},
      issn         = {2072-6651},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DZNE-2022-01439},
      pages        = {529},
      year         = {2022},
      note         = {CC BY: https://creativecommons.org/licenses/by/4.0/},
      abstract     = {OnabotulinumtoxinA, targeting the CGRP machinery, has been
                      approved for the last two decades for chronic migraine
                      prevention. The recently approved monoclonal antibodies
                      (mAbs) directed towards the calcitonin gene-related peptide
                      (CGRP) pathway open a new age for chronic migraine control.
                      However, some $40\%$ patients suffering from chronic
                      migraine is still resistant to treatment. The aim of this
                      work is to answer the following PICOS (participants
                      intervention comparator outcome study design) question: Is
                      there evidence of efficacy and safety of the combined
                      administration of anti-CGRP mAbs and onabotulinumtoxinA in
                      chronic migraine? A systematic review and meta-analysis
                      [Preferred Reporting Items for Systematic Reviews and
                      Meta-Analyses (PRISMA) 2020 recommendations] was made up to
                      19 April 2022. The results are encouraging: the combined
                      treatment proved to afford $≥50\%$ monthly headache days
                      (MHDs)/frequency reduction respect to baseline in up to
                      $58.8\%$ of patients; in comparison, anti-CGRP mAbs reduce
                      MHDs of 1.94 days from baseline and botulinum toxin of 1.86
                      days. Our study demonstrates for the first time that the
                      combination therapy of onabotulinumtoxinA with anti-CGRP
                      mAbs affords a reduction of 2.67 MHDs with respect to
                      onabotulinumtoxinA alone, with moderate certainty of
                      evidence. Adequately powered, good-quality studies are
                      needed to confirm the response to combination therapy in
                      terms of efficacy and safety. PROSPERO registration:
                      CRD42022313640.},
      keywords     = {Antibodies, Monoclonal: therapeutic use / Botulinum Toxins,
                      Type A: therapeutic use / Calcitonin Gene-Related Peptide:
                      antagonists $\&$ inhibitors / Drug Therapy, Combination:
                      adverse effects / Humans / Migraine Disorders: prevention
                      $\&$ control / Treatment Outcome / PRISMA 2020 (Other) /
                      anti-CGRP monoclonal antibodies (Other) / migraine (Other) /
                      onabotulinumtoxinA (Other) / pooled analysis (Other) /
                      Antibodies, Monoclonal (NLM Chemicals) / Botulinum Toxins,
                      Type A (NLM Chemicals) / Calcitonin Gene-Related Peptide
                      (NLM Chemicals)},
      cin          = {Scientific board / AG Bano},
      ddc          = {610},
      cid          = {I:(DE-2719)1030000 / I:(DE-2719)1013003},
      pnm          = {351 - Brain Function (POF4-351)},
      pid          = {G:(DE-HGF)POF4-351},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36006191},
      pmc          = {pmc:PMC9413678},
      doi          = {10.3390/toxins14080529},
      url          = {https://pub.dzne.de/record/165134},
}